BioCentury
ARTICLE | Clinical News

Actimmune: Phase III

August 4, 2003 7:00 AM UTC

ITMN will begin by year end a double-blind, placebo-controlled Phase III trial in about 600 IPF patients. Patients enrolled in the study in North America and Europe will be followed for at least 24 mo...